LABCORP HOLDINGS INC. — Form 8-K
Filed July 30, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 48/100
What the filing says
Labcorp reported Q2 2026 revenue of $3.73B (5.8% YoY growth) and adjusted EPS of $4.99 (14.9% growth vs. $4.35 prior year). The company raised full-year 2026 guidance: enterprise revenue growth to 5.4%–6.3% (up 30 bps midpoint) and adjusted EPS to $18.10–$18.55 (up $0.30 midpoint). Management announced $1.0B additional share repurchase authorization (total remaining $1.4B), retired $500M debt in June, invested $225.7M in acquisitions (Parkview Health lab services, Tribal Diagnostics), and launched consumer products (Marker genetic panel, AI-powered MyLabcorp app). Diagnostics Labs segment grew 5.5% revenue with 50 bps margin expansion; Biopharma Labs grew 6.5% with 130 bps margin expansion.
Why this rating
Solid organic growth (4.2%), margin expansion, and modest guidance raise are routine execution. $1.4B repurchase authorization (6.5% of $21.7B market cap) is material but incremental. M&A activity (~$226M/quarter) is small relative to company scale. No transformational event or material risk disclosed.
See more from July 30, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.